Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
1.600
0.00 (0.00%)
Nov 21, 2025, 9:30 AM EST
Silence Therapeutics Revenue
Silence Therapeutics had revenue of $159.00K in the quarter ending September 30, 2025, a decrease of -89.39%. This brings the company's revenue in the last twelve months to $25.83M, up 40.39% year-over-year. In the year 2024, Silence Therapeutics had annual revenue of $43.26M with 36.71% growth.
Revenue (ttm)
25.83M
Revenue Growth
+40.39%
P/S Ratio
11.52
Revenue / Employee
222.67K
Employees
116
Market Cap
297.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.26M | 11.62M | 36.71% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.84M | 28.82% |
| Dec 31, 2021 | 16.81M | 9.33M | 124.73% |
| Dec 31, 2020 | 7.48M | 7.16M | 2,214.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Mid-Atlantic Home Health Network | 27.00M |
| Tian'an Technology Group | 2.12M |
Silence Therapeutics News
- 13 days ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 19 days ago - Silence Therapeutics plc Non-GAAP EPS of -$0.15, revenue of $0.16M - Seeking Alpha
- 19 days ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 4 weeks ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 2 months ago - Silence Therapeutics (SLN) Receives Reiterated Buy Rating from HC Wainwright | SLN Stock News - GuruFocus
- 2 months ago - Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 3 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire